An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes.

Chen, Michael M; Roufosse, Florence; Wang, Sa A; Verstovsek, Srdan; Durrani, Sandy R; Rothenberg, Marc E; Pongdee, Thanai; Butterfield, Joseph; Lax, Timothy; Wechsler, Michael E; Stein, Miguel L; Ogbogu, Princess U; Kahwash, Basil; Mathur, Sameer K; Simon, Dagmar; Akuthota, Praveen; Holland, Nicole; Wetzler, Lauren; Ware, JeanAnne M; Guo, Canting; ... (2022). An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes. The journal of allergy and clinical immunology. In practice, 10(5), 1217-1228.e3. Elsevier 10.1016/j.jaip.2022.02.006

Preview

Text 1-s2.0-S2213219822001325-main.pdf - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (3MB) | Preview

BACKGROUND

Treatment of hypereosinophilic syndrome (HES) often requires the use of immunomodulators with substantial side effect profiles. The emergence of biologics offers an alternative treatment modality.

OBJECTIVE

To examine real world practice data to describe the safety and consequences of various biologics suspected to either directly or indirectly impact eosinophilic inflammation for the treatment of HES.

METHODS

Retrospective data from 13 centers were collected via an online REDCap data repository. Inclusion criteria included 1) peripheral eosinophil count ≥1500/mm3 without a secondary cause, 2) clinical manifestations attributable to the eosinophilia, and 3) having received mepolizumab (anti-IL-5), benralizumab (afucosylated anti-IL-5 receptor alpha), omalizumab (anti-IgE), alemtuzumab (anti-CD52), dupilumab (anti-IL-4 receptor alpha), or reslizumab (anti-IL-5) outside of a placebo-controlled clinical trial.

RESULTS

Of the 151 courses of biologics prescribed for 121 patients with HES, 59% resulted in improved HES symptoms and 77% enabled tapering of other HES medications. Overall, 105 patients were on daily systemic glucocorticoids at the time of a biologic initiation and were able to reduce their glucocorticoid dose by a median reduction of 10 mg of daily prednisone equivalents. Biologics were generally safe and well tolerated other than infusion reactions with alemtuzumab. Thirteen out of 24 patients had clinical improvement after switching biologics, and 9 patients responded to increasing the dose of mepolizumab after lack of response to a lower dose.

CONCLUSION

Biologics may offer a safer treatment alternative to existing therapies for HES, although the optimal dosing and choice for each subtype of HES remains to be determined. Limitations of this study include its retrospective nature and inter-site differences in data collection and availability of each biologic.

Interest & Impact

Downloads

83 since deposited on 21 Feb 2022
31 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item